Commentary: Theoretical Predictions of Flow Effects on Intestinal and Systemic Availability in Physiologically Based Pharmacokinetic Intestine Models: The Traditional Model, Segregated Flow Model, and QGut Model

Physiologically based pharmacokinetic (PBPK) models for the intestine, comprising of different flow rates perfusing the enterocyte region, were revisited for appraisal of flow affects on the intestinal availability (FI) and, in turn, the systemic availability (Fsys) and intestinal versus liver contribution to the first-pass effect during oral drug absorption. The traditional model (TM), segregated flow model (SFM), and effective flow (QGut) model stipulate that 1.0, ∼0.05 to 0.3, and ≤0.484× of the total intestinal flow, respectively, reach the enterocyte region that houses metabolically active and transporter-enriched enterocytes. The fractional flow rate to the enterocyte region (fQ), when examined under varying experimental conditions, was found to range from 0.024 to 0.2 for the SFM and 0.065 to 0.43 for the QGut model. Appraisal of these flow intestinal models, when used in combination with whole-body PBPK models, showed the ranking as SFM < QGut model < TM in the description of FI, and the same ranking existed for the contribution of the intestine to first-pass removal. However, the ranking for the predicted contribution of hepatic metabolism, when present, to first-pass removal was the opposite: SFM > QGut model > TM. The findings suggest that the fQ value strongly influences the rate of intestinal metabolism (FI and Fsys) and indirectly affects the rate of liver metabolism due to substrate sparing effect. Thus, the fQ value in the intestinal flow models pose serious implications on the interpretation of data on the first-pass effect and oral absorption of drugs.

[1]  K. Pang,et al.  Route-Dependent Metabolism of Morphine in the Vascularly Perfused Rat Small Intestine Preparation , 2000, Pharmaceutical Research.

[2]  Sara K. Quinney,et al.  Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin , 2010, Drug Metabolism and Disposition.

[3]  Michael B. Bolger,et al.  The composite solubility versus pH profile and its role in intestinal absorption prediction , 2008, AAPS PharmSci.

[4]  M. Morris,et al.  Formed and preformed metabolites: facts and comparisons , 2008, The Journal of pharmacy and pharmacology.

[5]  A Rostami-Hodjegan,et al.  Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.

[6]  Sara K Quinney,et al.  Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite , 2009, Drug Metabolism and Disposition.

[7]  K. Pang,et al.  Presence of a diffusional barrier on metabolite kinetics: enalaprilat as a generated versus preformed metabolite. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[8]  Baojian Wu Use of physiologically based pharmacokinetic models to evaluate the impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone. , 2012, Journal of pharmaceutical sciences.

[9]  J. Valentin Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[10]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[11]  S. Furlanetto,et al.  Development and evaluation of an in vitro method for prediction of human drug absorption I. Assessment of artificial membrane composition. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  K. Pang,et al.  1α,25-Dihydroxyvitamin D3 Up-Regulates P-Glycoprotein via the Vitamin D Receptor and Not Farnesoid X Receptor in Both fxr(−/−) and fxr(+/+) Mice and Increased Renal and Brain Efflux of Digoxin in Mice In Vivo , 2011, Journal of Pharmacology and Experimental Therapeutics.

[13]  Y. Sugiyama,et al.  Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  Michael B. Bolger,et al.  Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine , 2009, The AAPS Journal.

[15]  K. Pang,et al.  Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[16]  K. Pang,et al.  Why we need proper PBPK models to examine intestine and liver oral drug absorption. , 2012, Current drug metabolism.

[17]  K. Pang,et al.  Sequential first-pass elimination of a metabolite derived from a precursor , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[18]  Y. Horsmans,et al.  Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  Qing-Yu Zhang,et al.  Role of Intestinal Cytochrome P450 (P450) in Modulating the Bioavailability of Oral Lovastatin: Insights from Studies on the Intestinal Epithelium-Specific P450 Reductase Knockout Mouse , 2011, Drug Metabolism and Disposition.

[20]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[21]  K. Sandy Pang,et al.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  Kin-Kai Hwang,et al.  A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. , 2002, European journal of medicinal chemistry.

[23]  M. Fromm,et al.  Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin , 1996, Hepatology.

[24]  N. Chalasani,et al.  Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts , 2001, Hepatology.

[25]  A. Galetin,et al.  Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. , 2010, Drug metabolism and pharmacokinetics.

[26]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[27]  K. Pang,et al.  Absorption of benzoic acid in segmental regions of the vascularly perfused rat small intestine preparation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[28]  K. Pang,et al.  Disparity in Intestine Disposition between Formed and Preformed Metabolites and Implications: A Theoretical Study , 2009, Drug Metabolism and Disposition.

[29]  Harvey J. Clewell,et al.  A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair , 2012, Drug Metabolism and Disposition.

[30]  K. Pang,et al.  A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[31]  Kenji Tabata,et al.  Quantitative Prediction of Intestinal Metabolism in Humans from a Simplified Intestinal Availability Model and Empirical Scaling Factor , 2010, Drug Metabolism and Disposition.

[32]  Qing-Yu Zhang,et al.  The Role of Small-Intestinal P450 Enzymes in Protection against Systemic Exposure of Orally Administered Benzo[a]Pyrene , 2010, Journal of Pharmacology and Experimental Therapeutics.

[33]  Malcolm Rowland,et al.  Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[34]  D. Shen,et al.  First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.

[35]  R. Lledo-Garcia,et al.  A Pharmacokinetic Model for Evaluating the Impact of Hepatic and Intestinal First-Pass Loss of Saquinavir in the Rat , 2011, Drug Metabolism and Disposition.

[36]  K. Pang,et al.  Effect of diffusional barriers on drug and metabolite kinetics. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[37]  K. Pang,et al.  Physiological Modeling to Understand the Impact of Enzymes and Transporters on Drug and Metabolite Data and Bioavailability Estimates , 2010, Pharmaceutical Research.

[38]  Amir Heydari,et al.  Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA , 2006, Journal of psychopharmacology.

[39]  A. Galetin,et al.  Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. , 2009, Journal of pharmaceutical sciences.

[40]  Masoud Jamei,et al.  Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  H. Hirayama,et al.  First-pass metabolism of salicylamide. Studies in the once-through vascularly perfused rat intestine-liver preparation. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[42]  Jianghong Fan,et al.  Interplay of transporters and enzymes in drug and metabolite processing. , 2009, Molecular pharmaceutics.

[43]  K. Pang,et al.  P-Glycoprotein and an Unstirred Water Layer Barring Digoxin Absorption in the Vascularly Perfused Rat Small Intestine Preparation: Induction Studies with Pregnenolone-16α-carbonitrile , 2006, Drug Metabolism and Disposition.

[44]  Hong-Guang Xie,et al.  Extensive Intestinal First-Pass Elimination and Predominant Hepatic Distribution of Berberine Explain Its Low Plasma Levels in Rats , 2010, Drug Metabolism and Disposition.

[45]  Michael Gertz,et al.  Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.

[46]  P. Watkins,et al.  The erythromycin breath test predicts the clearance of midazolam , 1995, Clinical pharmacology and therapeutics.

[47]  Michael B Bolger,et al.  In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. , 2012, Molecular pharmaceutics.

[48]  K S Pang,et al.  Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect. , 1985, The Journal of pharmacology and experimental therapeutics.

[49]  K. Pang Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[50]  Michael Gertz,et al.  Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction , 2011, Drug Metabolism and Disposition.

[51]  T. Baillie,et al.  Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.

[52]  Jianghong Fan,et al.  PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. , 2010, Current drug metabolism.

[53]  R. Kimura,et al.  Hydroxyitraconazole, Formed During Intestinal First-Pass Metabolism of Itraconazole, Controls the Time Course of Hepatic CYP3A Inhibition and the Bioavailability of Itraconazole in Rats , 2008, Drug Metabolism and Disposition.

[54]  M. Pocard,et al.  Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. , 2010, Molecular pharmaceutics.

[55]  K. Pang,et al.  Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone conjugation in the serially perfused rat intestine and liver preparations. , 1997, The Journal of pharmacology and experimental therapeutics.

[56]  Y. Sugiyama,et al.  Transport of Drugs Across the Hepatic Sinusoidal Membrane: Sinusoidal Drug Influx and Efflux in the Liver , 2000, Seminars in liver disease.

[57]  P. Watkins,et al.  Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans , 2002, Clinical pharmacology and therapeutics.